Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA. Cohan SL, et al. Among authors: mendoza jp. Mult Scler Relat Disord. 2018 May;22:27-34. doi: 10.1016/j.msard.2018.02.028. Epub 2018 Feb 26. Mult Scler Relat Disord. 2018. PMID: 29524759 Free article. Clinical Trial.
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, Riester K, Mendoza JP, Livingston T, Jhaveri M. Ontaneda D, et al. Among authors: mendoza jp. Mult Scler Relat Disord. 2019 Jan;27:101-111. doi: 10.1016/j.msard.2018.09.038. Epub 2018 Oct 10. Mult Scler Relat Disord. 2019. PMID: 30368221 Free article.
Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Kresa-Reahl K, et al. Among authors: mendoza jp. Clin Ther. 2018 Dec;40(12):2077-2087. doi: 10.1016/j.clinthera.2018.10.011. Epub 2018 Nov 22. Clin Ther. 2018. PMID: 30470580
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Longbrake EE, et al. Among authors: mendoza jp. Mult Scler. 2021 May;27(6):883-894. doi: 10.1177/1352458520937282. Epub 2020 Jul 27. Mult Scler. 2021. PMID: 32716690 Free PMC article. Clinical Trial.
A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR, Kamath A, Button J, Kamath V, Mendoza JP, Zhu B, Plavina T, Woodward C, Penner N. Edwards KR, et al. Among authors: mendoza jp. Mult Scler Relat Disord. 2021 Jun;51:102861. doi: 10.1016/j.msard.2021.102861. Epub 2021 Feb 24. Mult Scler Relat Disord. 2021. PMID: 33773271
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC. Reder AT, et al. Among authors: mendoza jp. Mult Scler Relat Disord. 2021 Jun;51:102935. doi: 10.1016/j.msard.2021.102935. Epub 2021 Apr 8. Mult Scler Relat Disord. 2021. PMID: 33882426 Free article.
45 results